A preliminary clinical study in patients with resistant arterial hypertension (CVD risk factor) indicates high Syndecan-4 level as a potential marker for endothelial dysfunction [21]; moreover, the same HSPG has also been shown to regulate focal adhesions junctions, demonstrating the properties of a mechano-transducer effector [22], and importantly, its fragments generated following thrombin cleavage can modulate changes in endothelial barrier resistance [23]. The gene discussed is SDC4; the disease is endothelial dysfunction.